Epidemiology of Psoriasis in Portugal: A Population-Based Study
DOI:
https://doi.org/10.20344/amp.19048Keywords:
Arthritis, Psoriatic/epidemiology, Portugal, Psoriasis/epidemiology, Surveys and QuestionnairesAbstract
Introduction: Psoriasis is a common, chronic, and inflammatory skin disorder with a high personal, social and economic burden and important implications for healthcare systems. The aim of this study was to provide an epidemiological characterization of individuals with psoriasis in Portugal.
Material and Methods: A large observational, cross-sectional, nationwide, population-based survey study developed by the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology (GPP-SPDV). A structured questionnaire was designed and applied by experienced interviewers to a random, representative sample of Portuguese individuals with psoriasis and/or psoriatic arthritis. Patients were considered to have psoriasis if they replied positively to one of the following questions: “Does any physician have ever diagnosed you with psoriasis?” or “Do you have a skin disorder characterized by scaling, reddish skin lesions located in the elbows/knees/scalp?”.
Results: A total of 6381 individuals were interviewed, of which 283 met the criteria for psoriasis, corresponding to a prevalence rate of 4.4% (95% CI 3.95 – 4.98). Out of the participants that met psoriasis criteria, 24% had suggestive signs/symptoms but did not have a clinical diagnosis established and were not being monitored by a physician. Although more than 70% of participants had active disease (scaling, erythema, or pruritus) and one third had joint symptoms, only 12% were on systemic treatment. Fifty percent of participants with psoriasis (n = 139) had relevant comorbidities (most frequently depression/anxiety and cardiometabolic diseases). Sixteen percent of participants with psoriasis (n = 46) reported that psoriasis interfered with their daily activities (median impact of 5 in a 0 – 10 scale) and 12% mentioned the disease had an impact in their sexual life (median impact of 5 in a 0 – 10 scale).
Conclusion: The results of this study suggest that the prevalence rate of psoriasis is likely to be high in Portugal, and several gaps exist at different levels of healthcare delivery to these patients, from diagnosis to treatment. This study provides important data for the future planning of interventions targeting the improvement of psoriasis care in Portugal.
Downloads
References
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatology Venereol 2017;31:205–12. DOI: https://doi.org/10.1111/jdv.13854
Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–7. DOI: https://doi.org/10.1016/S0190-9622(99)70112-X
World Health Organization. Global report on psoriasis. Geneva: WHO; 2016.
Boehncke WH, Schön MP. Psoriasis. Lancet 2015;386:983–94. DOI: https://doi.org/10.1016/S0140-6736(14)61909-7
Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. Lancet 2021;397:1301–15. DOI: https://doi.org/10.1016/S0140-6736(20)32549-6
Massa A, Alves R, Amado J, Matos E, Sanches M, Selores M, et al. Prevalence of cutaneous lesions in Freixo de Espada à Cinta. Acta Med Port. 2000;13:247–54.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22:567–79. DOI: https://doi.org/10.1007/s40257-021-00598-4
Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician pesults from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016;17:87–97. DOI: https://doi.org/10.1007/s40257-015-0169-x
Enamandram M, Kimball AB. Psoriasis epidemiology: the interplay of genes and the environment. J Invest Dermatol. 2013;133:287–9. DOI: https://doi.org/10.1038/jid.2012.434
Zozaya N, Villoro R, Abdalla F, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, et al. Unmet needs in the management of moderate-tosevere psoriasis in Spain: a multidimensional evaluation. Acta Derm Venereol. 2022;102:adv00678. DOI: https://doi.org/10.2340/actadv.v102.583
Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016;13:1461–73. DOI: https://doi.org/10.1080/17425247.2016.1188801
Saraceno R, Griffiths CE. A European perspective on the challenges of managing psoriasis. J Am Acad Dermatol. 2006;54:81–4. DOI: https://doi.org/10.1016/j.jaad.2005.10.051
Lebwohl M, Thaçi D, Warren RB. Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. J Eur Acad Dermatol Venereol. 2021;35:35–41. DOI: https://doi.org/10.1111/jdv.17053
Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther. 2017;7:97–109. DOI: https://doi.org/10.1007/s13555-016-0153-2
Yang E, Beck K, Sanchez I, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis Targets Ther. 2018;8:41–7. DOI: https://doi.org/10.2147/PTT.S169389
Paul C, Guenther L, Torii H, Sofen H, Burge R, Lin CY, et al. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-tosevere psoriasis patients: 12-week results from two phase III trials. J Eur Acad Dermatol Venereol. 2018;32:68–72. DOI: https://doi.org/10.1111/jdv.14581
Torres T, Tavares Bello R, Paiva Lopes MJ, Menezes Brandão F, Ferreira A, Ferreira P, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy. Eur J Dermatol. 2020;30:645–54. DOI: https://doi.org/10.1684/ejd.2020.3945
Patel N, Nadkarni A, Cardwell LA, Vera N, Frey C, Patel N, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18:613–20. DOI: https://doi.org/10.1007/s40257-017-0279-8
Korman AM, Hill D, Alikhan A, Feldman SR. Impact and management of depression in psoriasis patients. Expert Opin Pharmacother. 2016;17:147–52. DOI: https://doi.org/10.1517/14656566.2016.1128894
Hölsken S, Krefting F, Schedlowski M, Sondermann W. Common fundamentals of psoriasis and depression. Acta Derm Venereol. 2021;101:1–9. DOI: https://doi.org/10.2340/actadv.v101.565
Puig L, Kirby B, Mallbris L, Strohal R. Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. Eur J Dermatol. 2014;24:305–11. DOI: https://doi.org/10.1684/ejd.2014.2299
Bulat V, Šitum M, Aždajiü MD, Lovriü I, Dediol I. Study on the impact of psoriasis on quality of life: psychological, social and financial implications. Psychiatr Danub. 2021;32:155–63.
Yamazaki F. Psoriasis: comorbidities. J Dermatol. 2021;48:732–40. DOI: https://doi.org/10.1111/1346-8138.15840
Szentkereszty-Kovács Z, Gáspár K, Szegedi A, Kemény L, Kovács D, Törőcsik D. Alcohol in Psoriasis — from bench to bedside. Int J Mol Sci. 2021;22:4987. DOI: https://doi.org/10.3390/ijms22094987
Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170:304–14. DOI: https://doi.org/10.1111/bjd.12670
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36:21–8. DOI: https://doi.org/10.1016/j.clindermatol.2017.09.005
Auker L, Cordingley L, Pye SR, Griffiths CE, Young HS. What are the barriers to physical activity in patients with chronic plaque psoriasis? Br J Dermatol. 2020;183:1094–102. DOI: https://doi.org/10.1111/bjd.18979
Correia B, Torres T. Obesity: A key component of psoriasis. Acta Biomed. 2015;86:121–9.
Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20:863–72. DOI: https://doi.org/10.1080/14656566.2019.1583207
Jensen P, Skov L. Psoriasis and Obesity. Dermatology. 2017;232:633–9. DOI: https://doi.org/10.1159/000455840
Fleming P, Kraft J, Gulliver WP, Lynde C. The relationship of obesity with the severity of psoriasis: A systematic review. J Cutan Med Surg. 2015;19:450–6. DOI: https://doi.org/10.1177/1203475415586332
Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163:586–92. DOI: https://doi.org/10.1111/j.1365-2133.2010.09941.x
Torres T, Alexandre JM, Mendonça D, Vasconcelos C, Silva BM, Selores M. Levels of physical activity in patients with severe psoriasis: a cross-sectional questionnaire study. Am J Clin Dermatol. 2014;15:129–35. DOI: https://doi.org/10.1007/s40257-014-0061-0
Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48:28–34. DOI: https://doi.org/10.1016/j.semarthrit.2018.01.003
Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242–8. DOI: https://doi.org/10.1016/j.jaad.2015.05.001
Puig L, van de Kerkhof PC, Reich K, Bachelez H, Barker J, Girolomoni G, et al. A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. J Eur Acad Dermatol Venereol. 2017;31:1176–82. DOI: https://doi.org/10.1111/jdv.14195
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
